Erbitux (cetuximab)

P3, N=89, Completed, Incyte Corporation | Active, not recruiting --> Completed

P2, N=70, Recruiting, Zhejiang University

P1, N=36, Recruiting, University of Chicago | Active, not recruiting --> Recruiting

P1/2, N=126, Recruiting, Genfleet Therapeutics (Shanghai) Inc.

The exploratory analysis of FIRE-3 suggests that the efficacy of cetuximab combined with FOLFIRI in RAS wild-type mCRC is related to sex and primary tumor sidedness. The results support the inclusion of patient sex into the design of future trials.

P2, N=130, Not yet recruiting, Merck Sharp & Dohme LLC

In addition, we conducted pathway enrichment analyses to elucidate the mechanisms underlying drug resistance for paclitaxel, 5-fluorouracil (5-FU), gemcitabine, and cetuximab. Importantly, our findings are consistent with prior experimental studies, providing literature-based validation of our results. Overall, our DNN-based TL approach achieved strong predictive performance across PDX & TCGA datasets and enrichment analyses provided valuable biological insights into drug resistance mechanisms.

P2, N=34, Active, not recruiting, University of Wisconsin, Madison | Recruiting --> Active, not recruiting | N=71 --> 34 | Trial completion date: Oct 2033 --> Oct 2029 | Trial primary completion date: Oct 2033 --> Oct 2029

dMMR/MSI-H mCRC is an entity with different tumor biology. We consider that dMMR/MSI-H mCRC patients with BRAF wild, MCS and subsequent IO have better outcomes with 1st line 5FU-based treatment with anti-VEGF/anti-EGFRs.

BRAF V600E is associated with inferior prognoses compared to BRAF WT in early-stage CC. This finding will help optimize trial design for this population.

P2, N=35, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting

P1, N=250, Not yet recruiting, Merck Sharp & Dohme LLC